PMC5055948_01
PMC5055948_02
(a) Patient with a CRVO develops recalcitrant macular edema associated with the use of travoprost. Also she is struggling to achieve her target IOP despite maximal medical management and elects to proceed with Ahmed Valve surgery. Pre-op VA is 20/60. (b) POD 1, IOP reduced to 0 mmHg off all antiglaucoma medications but placed on topical steroid difluprednate (Durezol, Alcon) at QID for the postoperative edema. POD 1 VA is 20/200. (c) POD 15 VA is 20/200 and, given the residual edema, intravitreal bevacizumab injection is given. (d) POD 36 VA improves to 20/60; IOP stabilizes at 14 mmHg while off all antiglaucoma medications and edema starts to resolve.
CRIOPM2016-2124581.003.jpg
PMC5055948_02_CRIOPM2016-2124581.003.jpg
fig3
TX) for treatment of primary open-angle glaucoma. The travoprost use was associated with inflammation and recalcitrant macular edema (Figure 3(a)). Alcon) was continued at qid; her VA was 20/200 (Figure 3(b)). At POD 15, she had residual macular edema and received a bevacizumab injection (Figure 3(c)). At POD 36, her vision was 20/60, the IOP had stabilized at 14 mmHg, and the macular edema has improved as shown (Figure 3(d)). At her most recent follow-up (post-op week 38) her IOP was 16 mmHg while off all antiglaucoma medications and her VA was 20/50.
PMC5055948_03